ResearchSafe

Asian-inclusive trial design and dose modeling, why this matters for peptide protocols

Posted by grinder265 in Protocols & Stacks - 1 points, 4 comments.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10083990

Found a paper on PMC about pushing more inclusive clinical research across Asia, basically arguing for model-informed drug development and translational work to set doses that actually fit different ethnic populations. The part that caught my eye was the focus on quantitative clinical pharmacology, population PK, and disease progression models to figure out regional dosing instead of just importing western defaults.

Ngl this is kind of where my head has been at lately. A lot of the compound data we reference gets built on populations that do not look like the people running these stacks, and then everyone just eyeballs a number and goes. If the pharmacokinetics can shift meaningfully between groups, it seems naive to assume a protocol transfers cleanly across the board without at least checking the math.

Curious how many of you actually adjust based on population PK data versus just copying whatever the bigger forums are running. Is anyone here using model-informed thinking when they plan a cycle, or is it still mostly vibes and bloodwork after the fact?

Comments

  • paul_j: Honestly most of this is over my pay grade but fwiw i think you're onto something, like even ignoring ethnicity stuff, half the dose talk on these forums is just guys parroting what the loudest poster said worked for them, which is basically nothing. The math matters even when people pretend it doesn't. I do wonder how much of the "responds differently" stuff is actually pharmacokinetics versus diet, body comp, sleep, or whatever else. Like sure population PK could matter, but also some dude ea
  • grinder265: Yeah ngl you kinda nailed the part that bugs me. Half the "responds differently" talk gets blamed on ethnicity when it's really just lifestyle variables nobody wants to track. Body comp, training load, sleep, macro split, all of that moves clearance and absorption way more than people want to admit. So even if the PK modeling was perfect for an ethnic subgroup, you'd still be off if you're not controlling for the obvious stuff. Which is why I'm kinda skeptical that adjusting for population alon
  • weekendnate: Yeah the parrot effect is real, someone runs X mg and posts good results and suddenly that's the gospel even when the person weighs 60 lbs more or has completely different baseline insulin sensitivity. On your other point, fair call, hard to untangle PK from lifestyle. Population PK models usually try to control for some of that with covariates like body weight and renal function, but diet and training rarely make it in. Probably undercounted honestly.
  • grinder265: Totally agree on the parrot thing, its honestly half the reason i started digging into the modeling papers instead of just trusting logs. And yeah the lifestyle covariates being missing is kind of the whole problem, like a hard training block is gonna move clearance and volume of distribution in ways most stacks dont account for at all. Do you know if any of the newer MIDD work is even trying to fold in activity level or HRV type stuff, or is that still too messy to model?

Community discussion - research and educational context only. Not medical advice.